| Identification | Back Directory | [Name]
2,6-Piperidinedione, 3-[6-[[4-(4-morpholinylmethyl)phenyl]methyl]-2-oxobenz[cd]indol-1(2H)-yl]- | [CAS]
2504233-68-3 | [Synonyms]
2,6-Piperidinedione, 3-[6-[[4-(4-morpholinylmethyl)phenyl]methyl]-2-oxobenz[cd]indol-1(2H)-yl]- | [Molecular Formula]
C28H27N3O4 | [MOL File]
2504233-68-3.mol | [Molecular Weight]
469.53 |
| Chemical Properties | Back Directory | [Boiling point ]
738.0±60.0 °C(Predicted) | [density ]
1.347±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO : 62.5 mg/mL (133.11 mM; ultrasonic and warming and heat to 60°C) | [form ]
Solid | [pka]
10.70±0.40(Predicted) | [color ]
Light yellow to yellow |
| Hazard Information | Back Directory | [Uses]
(Rac)-Cemsidomide ((Rac)-CFT7455) is the racemate of Cemsidomide (HY-144841) with antitumor activity[1]. Cemsidomide is a ubiquitin ligase pathway Ikaros/Aiolos degrader with molecular glue activity. Cemsidomide has a GI50 of 0.05 nM for NCIH929.1 cells. | [Biological Activity]
(Rac)-CFT7455 is a zinc finger transcription factors Ikaros (IKZF1) and Aiolos (IKZF3) degrader, acting via the ubiquitin proteasome pathway, with a GI50 of 0.05 nM for NCIH929.1 cells. (Rac)-CFT7455 is the racemic isomer of CFT7455 which is a IKZF1/IKZF3 degrader with anticancer activity[1][2]. | [storage]
Store at -20°C | [References]
[1]. David Proia et al. Advantageous therapies for disorders mediated by ikaros or aiolos. WO2022032132A1 (compound 5)[2]. James A. Henderson, et al. Abstract LB007: CFT7455: A novel, IKZF1/3 degrader that demonstrates potent tumor regression in IMiD-resistant multiple myeloma (MM) xenograft models. Cancer Res (2021) 81 (13_Supplement): LB007. |
|
|